



Cite this: *Org. Biomol. Chem.*, 2023, **21**, 5757

Received 23rd May 2023,  
Accepted 28th June 2023

DOI: 10.1039/d3ob00812f

rsc.li/obc

## Convenient synthesis of *N*-alkyl-3,1-benzoxazin-2-ones from carbamate protected anthranil aldehydes and ketones *via* one-step alkylation/alkoxy rearrangement†


Guang Tian, <sup>†a,b</sup> Wei-Li Jin, <sup>†c,b</sup> Chuanguang Qin <sup>\*a</sup> and Jie Wang <sup>\*b,c,d</sup>

A practical and step-economical protocol was developed to prepare *N*-alkyl-3,1-benzoxazin-2-one derivatives from anthranil aldehydes and ketones *via* one-step alkylation/alkoxy rearrangement, where three new chemical bonds and one ring were constructed in a single step. Control studies revealed a stepwise mechanism and that the alkoxy rearrangement was an inter-molecular process.

3,1-Benzoxazin-2-one is a valuable structural motif found in both natural products and pharmaceuticals and exhibits various important biological activities.<sup>1</sup> For example, the well-known efavirenz is a non-nucleoside reverse transcriptase inhibitor used to treat and prevent HIV/AIDS.<sup>2</sup> L-371257 and its analogs are a class of compounds acting as oxytocin receptor antagonists.<sup>1c,3</sup> Evodiamide A is a natural product isolated from the Chinese medicinal plant *Evodia rutaecarpa* (Juss.) and displays weak antibacterial activities (Scheme 1A).<sup>4</sup>

Due to the significance of 3,1-benzoxazin-2-one in medicinal chemistry, a plethora of synthetic methodologies have been developed to construct this moiety.<sup>5</sup> The *N*-alkylated 3,1-benzoxazin-2-one, in particular, is usually assembled using two different strategies (Scheme 1B). One of them relies on using *o*-aminoaryl methanol<sup>6</sup> or *o*-aminostyrene<sup>7</sup> as the starting material, which is first alkylated and then cyclized in the second step using a 1C carbonate equivalent, such as CO<sub>2</sub><sup>6b,c</sup> and CBr<sub>4</sub>.<sup>6a</sup> In the case of *o*-aminostyrene, additional steps are

usually necessary to transform the olefin through electrophilic activation,<sup>7a</sup> epoxide addition,<sup>7b</sup> or boryl Michael addition.<sup>7c</sup> Alternatively, the 3,1-benzoxazin-2-one moiety could be first constructed by cyclization, followed by a second step of alkylation under basic conditions.<sup>8</sup> Despite their synthetic validity, these routes typically involved multistep synthesis and required hazardous reagents such as Bu<sub>3</sub>SnH, phosgene, Me<sub>3</sub>Al, *etc.* Previous methods to construct the 3,1-benzoxazin-2-one (3') framework starting from carbamate protected anthranil aldehydes/ketones (1) normally involved hydride



**Scheme 1** A) Biologically active compounds containing 3,1-benzoxazin-2-one motifs. (B) Previous approaches toward *N*-alkyl-3,1-benzoxazin-2-ones. (C) Synthesis of 3,1-benzoxazin-2-ones using the carbamate protected anthranil aldehyde/ketone as the starting material.

<sup>a</sup>Department of Chemistry, Shanxi Key Laboratory of Polymer Science & Technology, MOE Key Laboratory of Supramolecular Material Physics & Chemistry, School of Chemical & Chemical Engineering, Northwestern Polytechnical University, Xi'an 710129, China. E-mail: qinchg@nwpu.edu.cn

<sup>b</sup>State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China. E-mail: jiewang@simm.ac.cn

<sup>c</sup>School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China

<sup>d</sup>University of Chinese Academy of Sciences, Beijing 100049, China

† Electronic supplementary information (ESI) available. CCDC 2258994. For ESI and crystallographic data in CIF or other electronic format see DOI: <https://doi.org/10.1039/d3ob00812f>

‡ These authors contributed equally to this work.



reduction<sup>9</sup> or organometallic addition<sup>10</sup> to the aldehyde/ketone followed by base mediated cyclization, where the alkoxy part of the carbamate was wasted as a leaving group (Scheme 1C). Here, in this work, we present a step-economical methodology to prepare *N*-alkyl 3,1-benzoxazin-2-one derivatives (**3**) from **1** via alkylation/alkoxy rearrangement in one step. In this reaction, the alkoxy group served not only as the leaving group but was also reincorporated into the final product. It is also noteworthy that three new carbon heteroatom bonds (one C–N and two C–O bonds) and one ring were constructed in a single step, which has rarely been reported in the synthesis of benzoxazinones.<sup>5h</sup>


An attempt to install a prenyl group on benzyl (2-formylphenyl) carbamate (**1a**) using prenyl bromide (**2a**) under NaH/DMF conditions failed to obtain the desired product **4a** even in the slightest amount (Table 1, entry 1). Instead, a significant amount (57%) of the deprotected alkylation product **5a** was obtained together with a new compound bearing the same mass as **4a** but missing the aldehyde functional group, whose structure was determined to be benzoxazinone **3a** by NMR spectrometry and confirmed unambiguously through X-ray crystallographic analysis. We then optimized the reaction conditions using **1a** and **2a** as the model substrates. Firstly, regular strong bases such as *t*BuOK, LDA and LiHMDS were evaluated and no **3a** could be detected, as indicated by crude NMR analysis (Table 1, entries 2–4). Solvent screening revealed that the reaction was messy in DMSO, while 1,4-dioxane, CH<sub>2</sub>Cl<sub>2</sub>, DCE and toluene were viable choices giving **3a** in

27–47% yields (entries 5–9). Although a slightly lower yield was obtained in toluene compared to CH<sub>2</sub>Cl<sub>2</sub> (41% vs. 47%), the reaction in toluene was cleaner, with essentially only two spots on TLC (**1a** and **3a**, 67% conversion) and neither of the unwanted **4a** or **5a** was detected. Thus, further efforts were made to improve the reaction conversion while fixing toluene as the solvent. Although raising the temperature did improve the conversion, the reaction was messy and the yield dropped to 33% (entry 10). Noticing that the reaction was heterogeneous due to the low solubility of NaH in toluene, 1.0 equiv. of 15-crown-5 was used as the additive and the yield could be improved to 75% (entry 11). Lastly, the addition of 0.6 equiv. of (*n*Bu)<sub>4</sub>NI to enhance the electrophilicity of the alkylation reagent could further increase the yield to 81%. Under the optimized conditions, an isolated yield of 80% was obtained on a 0.3 mmol scale (entry 12).

With the optimized conditions in hand, we set out to explore the scope of this reaction. Firstly, different carbamate protecting groups were evaluated (Scheme 2A). Other than Cbz, common carbamate protecting groups bearing the primary alkoxy group such as CO<sub>2</sub>Et, Troc, Alloc and *p*-nitrobenzyloxycarbonyl were well tolerated and afforded the corresponding benzoxazinone products **3b–3e** in moderate to good yields (57%–68%). The Boc protecting group bearing a bulky tertiary *tert*-butoxy group didn't work well under the standard conditions, probably due to the relatively high stability of Boc under basic conditions.<sup>11</sup> Nonetheless, under slightly modified conditions (50 °C, omit the addition of 15-crown-5 and TBAI), a useful yield of 48% could also be obtained (**3f**). Moreover, aryloxy containing carbamate could be well tolerated, furnishing the corresponding product (**3g**) in 61% yield.

Next, substitutions on the benzene ring of anthranil aldehyde were investigated (Scheme 2B). Moderate electron-rich substrates (**6a–6d**) were converted to the benzoxazinone products in good to excellent yields (70%–90%). All types of halides (**6e–6i**) including aryl iodide were well tolerated, setting up an orthogonal reactive site for further derivatization. Strong electron withdrawing (**6j**) and donating groups (**6k**) led to products in moderate yields (55% and 45%), possibly due to the substantial influence of these functional groups on the nucleophilicity of nitrogen and the electrophilic nature of the aldehyde. By replacing the benzene group with naphthylene, the corresponding naphtho[2,3-*d'*][1,3]oxazin-2-one **6l** could also be prepared in a high yield (85%). Compared to aldehydes, anthranil ketone substrates would provide products possessing a quaternary carbon at C4, which is structurally more convincing and difficult to realize due to steric hindrance and retarded electrophilicity at the carbonyl group. Gratifyingly, our reaction also proceeded uneventfully with both methyl ketone and trifluoromethyl ketone substrates and provided the corresponding products (**6m** and **6n**) in moderate yields without further optimization, the latter of which (**6n**) constituted the alkylated version of an important class of efavirenz analogs.<sup>12</sup> However, 6-substituted (Me or Br) substrates are not compatible in this chemistry. Under the same conditions, only the alkylation products were obtained and could


Table 1 Optimization of reaction conditions




Entry <sup>a</sup>	Base	Solvent	Conversion	Yield ( <b>3a/4a/5a</b> ) <sup>b</sup>
1	NaH	DMF	>95%	42%/nd/57%
2	<i>t</i> BuOK	DMF	80%	nd/5%/<5%
3	LDA	DMF	45%	nd/11%/nd
4	LiHMDS	DMF	45%	nd/11%/nd
5	NaH	DMSO	>95%	nd/nd/nd
6	NaH	1,4-Dioxane	67%	27%/nd/10%
7	NaH	CH <sub>2</sub> Cl <sub>2</sub>	>95%	47%/5%/<5%
8	NaH	DCE	>95%	33%/45%/5%
9	NaH	Toluene	67%	41%/nd/nd
10 <sup>c</sup>	NaH	Toluene	>95%	33%/nd/nd
11 <sup>d</sup>	NaH	Toluene	>95%	75%/nd/12%
12 <sup>e</sup>	NaH	Toluene	>95%	81% (80%) <sup>f</sup> /nd/11%

<sup>a</sup> Reaction conditions: carbamate **1a** (0.1 mmol), bromide **2a** (1.5 equiv.), and base (3.0 equiv.) were stirred in 1.0 mL of solvent at 0 °C for 1 h and then room temperature for another 2 h. <sup>b</sup> Yields determined by crude <sup>1</sup>H NMR using trimethoxybenzene as the internal standard. <sup>c</sup> The reaction was run at 50 °C. <sup>d</sup> Addition of 15-crown-5 (1.0 equiv.). <sup>e</sup> Addition of 15-crown-5 (1.0 equiv.) and (*n*Bu)<sub>4</sub>NI (0.6 equiv.). <sup>f</sup> Isolated yield on a 0.3 mmol scale. nd = not detected.







**Scheme 3** A) Gram-scale synthesis and synthetic transformations. (B) Crossover experiments. (C) Investigation of the reaction intermediates. (D) Plausible reaction mechanism. <sup>a</sup> Yield determined by crude <sup>1</sup>H NMR using trimethoxybenzene as the internal standard.

nism (Scheme 3B). Next, under the standard conditions in the absence of 2a, aldehyde 1a was recovered in 91% yield, while 4a was successfully converted to 3a in 60% yield along with 21% of the de-Cbz product 5a. The same reaction was sluggish in the absence of 15-crown-5, with only 18% of 3a obtained and 71% of 4a untouched, as indicated by crude NMR analysis (Scheme 3C). These experiments indicated that 4a was a possible intermediate in the reaction and that the *N*-alkylation took place prior to the alkoxy rearrangement step.

Based on these experiments, a plausible reaction mechanism is outlined, as shown in Scheme 3D. Carbamate 1 first underwent *N*-alkylation to produce the alkylated product 4. The basic reaction conditions would then cause partial decomposition of the carbamate group and release a small amount of alkoxide,<sup>14</sup> which would proceed to attack the aldehyde or ketone and induce downstream intramolecular cyclization<sup>9,10</sup> to form the thermodynamically stable *N*-alkyl-3,1-benzoxazin-2-one product. The same alkoxide was continuously regenerated in this process and actually involved in the reaction as a catalyst. The role of 15-crown-5 was believed to be multifaceted, namely, facilitating the *N*-alkylation step and accelerating both carbamate decomposition and subsequent alkoxide attack on the aldehyde/ketone.

## Conclusions

In summary, we have developed a simple method to synthesize *N*-alkyl-3,1-benzoxazin-2-one derivatives from carbamate protected anthranil aldehydes and ketones *via* a one-step alkylation/alkoxy rearrangement reaction. This protocol uses feed-stock reagents for constructing three carbon-hetero bonds and

one ring in a single step and has a broad substrate scope. Control studies revealed that *N*-alkylation took place prior to the ring closing step and that the alkoxy transfer was an intermolecular process. The modular and highly step-economical nature would make this chemistry attractive for benzoxazinone analog synthesis.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

Financial support for this work was provided by the National Natural Science Foundation of China (Grant No. 22101290), the Chinese Academy of Sciences and the Shanghai Institute of Materia Medica.

## References

- (a) S. J. Robinson, B. I. Morinaka, T. Amagata, K. Tenney, W. M. Bray, N. C. Gassner and P. Crews, *J. Med. Chem.*, 2010, **53**, 1651–1661; (b) V. Namasivayam, M. Vanangamudi, V. G. Kramer, S. Kurup, P. Zhan, X. Liu and S. N. Byraredy, *J. Med. Chem.*, 2018, **62**, 4851–4883; (c) P. D. Williams, B. V. Clineschmidt, J. M. Erb, R. M. Freidinger, M. T. Guidotti, E. V. Lis and D. R. Reiss, *J. Med. Chem.*, 1995, **38**, 4634–4636; (d) P. Zhang, E. A. Terefenko, A. Fensome, J. Wrobel, R. Winneker,





- S. Lundeen, K. B. Marschke and Z. Zhang, *J. Med. Chem.*, 2002, **45**, 4379–4382; (e) A. Fensome, R. Bender, R. Chopra, J. Cohen, M. A. Collins, V. Hudak, K. Malakian, S. Lockhead, A. Olland, K. Svenson, E. A. Terefenko, R. J. Unwalla, J. M. Wilhelm, S. Wolfrom, Y. Zhu, Z. Zhang, P. Zhang, R. C. Winneker and J. Wrobel, *J. Med. Chem.*, 2005, **48**, 5092–5095; (f) T. Mizutani, S. Ishikawa, T. Nagase, H. Takahashi, T. Fujimura, T. Sasaki, A. Nagumo, K. Shimamura, Y. Miyamoto, H. Kitazawa, M. Kanesaka, R. Yoshimoto, K. Aragane, S. Tokita and N. Sato, *J. Med. Chem.*, 2009, **52**, 7289–7300.
- 2 M. M. Bastos, C. C. P. Costa, T. C. Bezerra, F. C. da Silva and N. Boechat, *Eur. J. Med. Chem.*, 2016, **108**, 455–465.
- 3 P. D. Williams, M. G. Bock, B. E. Evans, R. M. Freidinger, S. N. Gallicchio, M. T. Guidotti and C. J. Woyden, *Bioorg. Med. Chem. Lett.*, 1999, **9**, 1311–1316.
- 4 X. L. Su, S. Xu, Y. Shan, M. Yin, Y. Chen, X. Feng and Q. Z. Wang, *Fitoterapia*, 2018, **127**, 186–192.
- 5 (a) P. D. Champlain, J.-L. Luche, R. A. Marty and P. D. Mayo, *Can. J. Chem.*, 1976, **54**, 3749–3756; (b) S. S. Nikam, P.-W. Yuen, B. E. Kornberg, B. Tobias and M. F. Rafferty, *J. Org. Chem.*, 1997, **62**, 9331–9334; (c) Y. Nishiyama, Y. Naitoh and N. Sonoda, *Synlett*, 2004, 886–888; (d) E. Hernandez, J. M. Velez and C. P. Vlaar, *Tetrahedron Lett.*, 2007, **48**, 8972–8975; (e) K. Kobayashi, S. Fukamachi and H. Konishi, *Heterocycles*, 2008, **75**, 2301–2307; (f) O. R. Suárez-Castillo, C. I. Bautista-Hernández, M. Sánchez-Zavala, M. Meléndez-Rodríguez, A. Sierra-Zenteno, M. S. Morales-Ríos and P. Joseph-Nathan, *Heterocycles*, 2012, **85**, 2147–2171; (g) Y. M. Yu, Y. N. Huang and J. Deng, *Org. Lett.*, 2017, **19**, 1224–1227; (h) S. Sun, C. Zhou, J. T. Yu and J. Cheng, *Org. Lett.*, 2019, **21**, 6579–6583; (i) H. Xiong, X. Wu, H. Wang, S. Sun, J. T. Yu and J. Cheng, *Adv. Synth. Catal.*, 2019, **361**, 3538–3542; (j) M. Vayer, M. Pastor, C. Kofink and N. Maulide, *Org. Lett.*, 2022, **24**, 27–32; (k) X. Li, J. Benet-Buchholz, E. C. Escudero-Adan and A. W. Kleij, *Angew. Chem., Int. Ed.*, 2023, **62**, e202217803.
- 6 (a) Y. Zhao, B. Huang, C. Yang, Q. Chen and W. Xia, *Org. Lett.*, 2016, **18**, 5572–5575; (b) T. Niemi, I. Fernandez, B. Steadman, J. K. Mannisto and T. Repo, *Chem. Commun.*, 2018, **54**, 3166–3169; (c) T. V. Tran, Y. Shen, H. D. Nguyen, S. Deng, H. Roshandel, M. M. Cooper, J. R. Watson, J. A. Byers, P. L. Diaconescu and L. H. Do, *Green Chem.*, 2022, **24**, 9245–9252.
- 7 (a) K. Kobayashi, S. Fukamachi, D. Nakamura, O. Morikawa and H. Konishi, *Heterocycles*, 2008, **75**, 95–105; (b) H. Fan, Y. Wan, P. Pan, W. Cai, S. Liu, C. Liu and Y. Zhang, *Chem. Commun.*, 2019, **56**, 86–89; (c) E. M. Larin, A. Torelli, J. Loup and M. Lautens, *Org. Lett.*, 2021, **23**, 2720–2725.
- 8 (a) J. C. Kern, E. A. Terefenko, A. Fensome, R. Unwalla, J. Wrobel, Y. Zhu, J. Cohen, R. Winneker, Z. Zhang and P. Zhang, *Bioorg. Med. Chem. Lett.*, 2007, **17**, 189–192; (b) K. C. Nicolaou, A. Krasovskiy, U. Majumder, V. E. Trepanier and D. Y. Chen, *J. Am. Chem. Soc.*, 2009, **131**, 3690–3699; (c) V. Palomo, D. I. Perez, C. Roca, C. Anderson, N. Rodriguez-Muela, C. Perez, J. A. Morales-Garcia, J. A. Reyes, N. E. Campillo, A. M. Perez-Castillo, L. L. Rubin, L. Timchenko, C. Gil and A. Martinez, *J. Med. Chem.*, 2017, **60**, 4983–5001.
- 9 J. L. Garcia Ruano, C. Pedregal and J. H. Rodriguez, *Tetrahedron*, 1989, **45**, 203–214.
- 10 (a) L. A. Radesca, Y. S. Lo, J. R. Moore and M. E. Pierce, *Synth. Commun.*, 1997, **27**, 4373–4384; (b) G.-J. Mei, C.-Y. Bian, G.-H. Li, S.-L. Xu, W.-Q. Zheng and F. Shi, *Org. Lett.*, 2017, **19**, 3219–3222.
- 11 N. J. Tom, W. M. Simon, H. N. Frost and M. Ewing, *Tetrahedron Lett.*, 2004, **45**, 905–906.
- 12 A. J. Cocuzza, D. R. Chidester, B. C. Cordova, S. Jeffrey, R. L. Parsons, L. T. Bacheler, S. Erickson-Viitanen, G. L. Trainor and S. S. Ko, *Bioorg. Med. Chem. Lett.*, 2001, **11**, 1177–1179.
- 13 H. C. Kolb, M. G. Finn and K. B. Sharpless, *Angew. Chem., Int. Ed.*, 2001, **40**, 2004–2021.
- 14 L. W. Dittert and T. Higuchi, *J. Pharm. Sci.*, 1963, **52**, 852–857.

